Biochemical etiology of Alzheimer’s disease relates it to :
## Core Concept
The biochemical etiology of Alzheimer's disease is primarily related to the abnormal processing of amyloid precursor protein (APP), leading to the accumulation of amyloid-beta peptides and the formation of neurofibrillary tangles. This process involves various enzymes and proteins, including presenilin, which plays a critical role in the gamma-secretase complex. The dysregulation of these processes contributes to neuronal damage and death.
## Why the Correct Answer is Right
The correct answer, **C. Amyloid beta**, is right because Alzheimer's disease is pathologically characterized by the accumulation of amyloid-beta peptides in the brain, forming senile plaques, and the aggregation of tau protein into neurofibrillary tangles. Amyloid-beta is produced from APP through a series of enzymatic cleavages by beta-secretase and gamma-secretase. The deposition of amyloid-beta is thought to trigger a cascade of events leading to neuronal injury and death.
## Why Each Wrong Option is Incorrect
- **Option A:** While apolipoprotein E (APOE) is a risk factor for Alzheimer's disease, particularly the ε4 allele, it is not considered a direct biochemical cause but rather a genetic risk factor that may influence amyloid-beta aggregation or clearance.
- **Option B:** Presenilin is a component of the gamma-secretase complex, which is crucial for the cleavage of APP to produce amyloid-beta. However, presenilin itself is not the direct biochemical etiology but rather a critical factor in the amyloid-beta production pathway.
- **Option D:** While tau protein and its aggregation into neurofibrillary tangles are hallmarks of Alzheimer's disease, the primary biochemical etiology relates more directly to the abnormal processing and accumulation of amyloid-beta.
## Clinical Pearl / High-Yield Fact
A key clinical pearl is that the amyloid cascade hypothesis, which posits that amyloid-beta accumulation is the primary driver of Alzheimer's disease pathology, has led to the development of several therapeutic strategies aimed at reducing amyloid-beta levels or preventing its aggregation.
## Correct Answer: C. Amyloid beta